Vermillion Q2 Revenues Up 65 Percent; OVA1 Sales Down Slightly | GenomeWeb

This story has been updated with comments from a company earnings call.

NEW YORK (Genomeweb News) – Vermillion reported today that its second quarter revenues were $535,000, up 65 percent from $324,000 in Q2 2014 but falling short of the average Wall Street estimate of $1.2 million.

The company posted product revenue of $535,000, up 153 percent from $211,000 in Q2 2014. It had no license revenue, compared to $113,000 in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.